Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations. We have assembled a world-class team that we need to realize this vision, including creative scientific pioneers in genetics, experienced company builders, and biotech industry leaders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/28/19 | $191,000,000 | Seed |
Alexandria Venture Investments ARCH Venture Partners Casdin Capital Foresite Capital Third Rock Ventures  | undisclosed |
| 01/10/22 | $190,000,000 |
Andreessen Horowitz Bio+Health Casdin Capital City Hill Ventures Driehaus Capital Management Foresite Capital Matrix Capital Management Moore Strategic Ventures NS Investment Terra Magnum Capital Partners Woodline Partners | undisclosed | |
| 12/03/24 | $115,000,000 | Series D |
Andreessen Horowitz ARCH Venture Partners Casdin Capital Deep Track Capital Foresite Capital Frazier Life Sciences General Catalyst Partners GV Janus Henderson Investors Logos Capital Matrix Capital Management Moore Strategic Ventures Piper Heartland Healthcare Capital Third Rock Ventures Woodline Partners | undisclosed |
